The clinical benefits of vitamin D therapy have received substantial attention over the past decade. Recently, several trials looked to clarify the optimal vitamin D dose or serum level needed to promote human health. The purpose of this review is to highlight selected studies published since January 2015.
INTRODUCTION
Vitamin D is a steroid hormone called the 'sunshine vitamin' because skin exposure to ultraviolet light coverts provitamin-7-dehydrocholesterol into vitamin D. National Health and Nutrition Examination Survey 2000-2004 [1] documented that $75% of adults had vitamin D insufficiency, defined as a serum 25-hydroxyvitamin D [25(OH)D] levels less than 30 ng/ml [2] . The epidemic was attributed to a transition from outdoor to indoor work. Blacks and Hispanics had lower 25(OH)D levels than whites [1] , a phenomenon attributed to greater skin melanin causing lower cutaneous vitamin D synthesis.
Measurement of vitamin D
Vitamin D-binding protein (VDBP) transports vitamin D metabolites in serum [3 && ]. Up to 90% of vitamin D is bound to VDBP, $10% binds to albumin, and less than 1% circulates in the free form. The free and albumin-bound vitamin D are considered bioavailable. Thus, VDBP levels could be used to estimate bioavailable vitamin D. VDBP has three major isoforms and two glycosylation patterns, resulting in six configurations that differ in binding affinity and differ by race.
In 2013, researchers reported that racial differences in VDBP explained why blacks had apparently lower 25(OH)D levels, yet higher bone mineral density (BMD) than whites [4] . In that study, which used a monoclonal assay to measure VDBP, blacks had lower VDBP levels than whites. When researchers calculated bioavailable 25(OH)D levels based on VDBP levels, they found that 25(OH)D levels were similar across races. However, a 2016 study [3 && ] concluded that the assay used to measure VDBP in the 2013 study was biased, leading to incorrect conclusions about racial differences in bioactive vitamin D levels.
Three methods of measuring VDBP exist. A recently developed liquid chromatographytandem mass spectrometry (LC-MS/MS) assay [5 & ] is considered the gold standard assay. The second and third methods measure VDBP using monoclonal and polyclonal ELISA. Denburg et al. [3 && ] concluded that VDBP levels within individuals vary by the assay utilized. They used all three assays to measure VDBP in 125 older adults with chronic kidney disease. Blacks had lower VDBP using the monoclonal ELISA compared with the other two methods of measurement. VDBP did not vary by genotype or race when using LC-MS/MS. Therefore, bound and bioactive vitamin D levels were significantly lower in blacks than whites. The polyclonal ELISA showed acceptable performance characteristics compared with the LC-MS/MS, representing a less expensive yet accurate method by which to measure VDBP.
For now, clinicians should continue to use serum 25(OH)D levels to assess vitamin D status in patients, regardless of their race. However, the polyclonal ELISA shows potential for future measurement of bioactive vitamin D in selected circumstances.
Vitamin D supplements during pregnancy
Interventions that increase peak bone mass could potentially reduce an individual's lifetime risk of osteoporosis. Indeed, the skeletal benefits of vitamin D likely have greatest impact in the rapidly growing skeleton. Researchers [6 & ] theorized that vitamin D supplementation during pregnancy might increase neonatal bone mineral content (BMC), and designed a study to test this hypothesis.
The Maternal Vitamin D Osteoporosis Study [6 & ] was a randomized, double-blind, placebo-controlled trial conducted at three UK sites. Women at least 19 years old with a singleton pregnancy and a serum 25(OH)D level of 10-40 ng/ml were randomized, before 17 weeks' gestation, to placebo or vitamin D 3 1000 IU once a day until delivery. The primary outcome was neonatal whole body BMC within 2 weeks of birth.
A total of 1134 women ages 31 AE 5 years old were randomized into the trial, but 298 (26%) withdrew before measurement of their child's BMC. Additionally, only 737 of 836 (88%) of infants had valid measures of BMC because of motion artifact. In completers (65% of randomized pregnancies), there was no difference in neonatal BMC between treatment arms. However, in a planned post hoc analysis of babies born in winter months (December to February), the vitamin D 3 arm (n ¼ 74) had higher whole body BMC than the placebo arm (n ¼ 64, 5.5 g, P ¼ 0.004).
In summary, the study did not support widespread use of vitamin D 3 for pregnant women to increase BMC of their infants. However, BMC was approximately 9% higher in babies born in winter. Researchers plan to follow all children in the trial to evaluate whether such skeletal benefits persist with time.
Optimal serum vitamin D levels in postmenopausal women
Experts have hotly debated the optimal serum vitamin D level needed for human health. The Institute of Medicine (IOM) [7] concluded that virtually all people were vitamin D replete, with serum 25(OH)D levels at least 20 ng/ml. By contrast, other experts argued that serum levels at least 30 ng/ml indicated optimal status [2] . Such disagreement was possible because prior trials compared vitamin D and calcium with placebo, did not recruit study participants based on initial vitamin D levels, or did not target a high vitamin D level during the trial. Researchers [8 & ] therefore designed a study to directly address ongoing controversy about the optimal serum vitamin D level needed to support musculoskeletal health.
Researchers recruited 230 postmenopausal women with 25(OH)D levels of 14-27 ng/ml into a 1-year trial [8 & ]. One-third of study participants received placebo, one-third received low-dose vitamin D 3 (800 IU/day), and one-third received a highdose vitamin D 3 regimen chosen to quickly raise and maintain 25(OH)D levels more than 30 ng/ml throughout the trial. Because the primary effect of vitamin D is to promote active intestinal calcium absorption, the primary study outcome was the change in calcium absorption, measured using the gold standard dose-corrected ratio of two stable isotopes in a 24-h urine collection [9] . Other study outcomes included changes in spine, hip and total body BMD, timed-up-and-go and fivetimes-sit-to-stand tests, muscle mass, and falls.
KEY POINTS
In postmenopausal women with 25(OH)D levels around 20 ng/ml at baseline, high-dose vitamin D increased calcium absorption by 1% with no effect on BMD, physical function, or falls compared with low-dose vitamin D or placebo.
In adults at least 70 years old, high-dose vitamin D promoted falls.
Vitamin D increased risk and duration of URIs in adults.
Vitamin D had no effect on the risk of new colon adenomas.
Update on vitamin D Hansen and Johnson
Attrition was very low as 226 women (96%) completed the study. Additionally, adherence to study pills approached 100%.
Study participants randomized to high-dose vitamin D experienced a small, but statistically significant increase (1%) in intestinal calcium absorption compared with study participants randomized to low-dose vitamin D and placebo. However, the small increase in calcium absorption did not translate into changes in BMD, functional status, muscle mass, or falls. Study limitations included exclusion of women with osteoporosis, recruitment of predominantly white study participants, and short study duration. Although short in duration, based on another trial [10] , the study had 90% power to detect a 1% change in mean total hip BMD between the three arms. Thus, the trial did not support the widespread clinical practice of correcting serum 25(OH)D to levels at least 30 ng/ml.
Optimal vitamin D dose needed to reduce falls and preserve muscle function
Vitamin D deficiency causes muscle weakness [11] . Several studies reported that vitamin D therapy reduces the risk of falling, with a notable exception [12] in which once yearly high-dose vitamin D increased the risk of falls. Most researchers have detected vitamin D receptors in muscle cells, providing biologic plausibility that vitamin D favorably affects muscle strength, reducing falls. However, researchers continue to debate the vitamin D dose needed to promote muscle health.
A recent trial [13 && ] directly addressed ongoing controversy about the optimal vitamin D dose needed to reduce risk of falling. Researchers recruited ambulatory adults at least 70 years of age who fell at least once yearly into a clinical trial. Study participants were not recruited based on initial serum 25(OH)D levels, although those taking more than 800 IU vitamin D daily were excluded. Two-hundred study participants with baseline 25(OH)D levels of $19 AE 9 ng/ml were randomized to one of three monthly vitamin D regimes for 1 year: 24 000 IU vitamin D 3 , 60 000 IU vitamin D 3 , or 24 000 IU vitamin D 2 plus 24 000 IU vitamin D 3 . Primary study outcomes were the Short Physical Performance Battery Score and the 25(OH)D level achieved by treatment arm. The secondary outcome was the number of falls determined by diaries and monthly phone calls.
Although 25(OH)D levels increased to the greatest degree in the 48 000 IU/month arm, there was no difference between treatment arms in the Short Physical Performance Battery Score [13 && ]. Moreover, falls were most frequent among study participants randomized to the highest vitamin D dose. The incidence of falls was 48, 66, and 70% in the 24 000 IU, 60 000 IU, and the 24 000 IU vitamin D 2 plus 24 000 IU vitamin D 3 arms, respectively (P ¼ 0.048). In summary, higher vitamin D doses given once monthly increased the risk of falling, similar to results of an earlier placebocontrolled trial in which 500 000 IU of vitamin D intramuscular once yearly increased falls [12] .
In a second trial [14] , researchers studied the effect of vitamin D therapy on muscle strength and lean mass. Brazilian postmenopausal women 50-65 years old with at least one yearly fall were eligible for the trial. Women with osteopenia, and/or impaired balance, cognition, vision, hearing, and/or use of bone active medications were excluded. Women were randomized to vitamin D 3 1000 IU or placebo once daily for 9 months. The study was powered to detect differences in falls. Other outcomes included changes in handgrip strength, the chair rising test score, and lean body mass by whole body BMD.
A total of 160 women ages 59 AE 7 years old with initial 25(OH)D levels 15 AE 8 ng/ml were randomized into the trial [14] . Falls were not reported. The 9-month change in lean mass and handgrip strength were no different between treatment arms, but the chair rising test did improve with vitamin D. Women randomized to vitamin D could perform three additional chair rises at 9 months (13 AE 6 chair rises at baseline, 16 AE 5 at 9 months, P < 0.001). By contrast, placebo-treated women experienced no change in chair rises (13 AE 6 at baseline, 13 AE 5 at 9 months, P ¼ 0.773).
The trials described call for caution when prescribing high-dose vitamin D to improve muscle function or falls, particularly as intermittent bolus doses. It is possible that lower vitamin D levels in the second trial explain improved chair rise tests in that study. Differing bioavailable vitamin D levels by race is a second potential explanation.
Optimal vitamin D dose needed to reduce respiratory infections
Cells of the immune system express the vitamin D receptor [15] . In observational studies, higher vitamin D levels are associated with lower rates of respiratory infection [16] . Thus, investigators [17 & ] hypothesized that vitamin D therapy would reduce the rate of acute respiratory infections (ARI).
Researchers recruited residents living in sheltered housing, and their caregivers, into a 1-year clinical trial [17 was assessed at baseline, but a predefined serum vitamin D level was not required for inclusion.
Residents, and their caregivers within the same housing unit, were randomized together into active or placebo therapy. The housing unit approach to randomization was a key element of the trial, as an infection in one member would likely spread to others sharing the same place. In the high-dose vitamin D arm, residents received vitamin D 3 96 000 IU every 2 months plus 400 IU vitamin D 3 daily; their caregivers received vitamin D 3 120 000 IU vitamin D3 every 2 months. In the placebo arm, residents received placebo pills every 2 months plus 400 IU vitamin D 3 daily; their caregivers received placebo pills every 2 months. The primary study outcome was time to first ARI; secondary outcomes included rates and duration of upper and lower respiratory tract infections (LRIs). Researchers used the Jackson criteria to diagnose cold [18] and cough, fever, and myalgia to diagnose influenza; together these events reflected incident upper respiratory infections (URIs). The Macfarlane [19] symptom score was used to define LRIs. ARI included all URIs and LRIs. In a subset of study participants, researchers tested nasopharyngeal secretions for 10 common viral infections.
A total of 240 adults were randomized into the 1-year trial [17 & ]. Baseline serum 25(OH)D levels were 17 AE 9 and 18 AE 9 ng/ml in the active and placebo arms, respectively, and only 8% of study participants had levels at least 30 ng/ml. Time to first ARI was no different between treatment arms [adjusted hazard ratio 1.18, 95% confidence interval (CI) 0.84-1.74]. However, the high-dose vitamin D arm experienced an increased risk (hazard ratio 1.48, 95% CI 1.02-2.16) and greater duration (median of 7 versus 5 days, P ¼ 0.005) of URI than the placebo arm.
In another study [20 & ], researchers investigated the effect of vitamin D therapy on risk of URI in adults with mild-to-moderate asthma and initial 25(OH)D levels less than 30 ng/ml. The study was a planned post hoc analysis of the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness or 'VIDA' trial designed to assess whether vitamin D affected asthma control. Researchers randomized 203 study participants to placebo or vitamin D 3 100 000 IU on day 1 then 4000 IU daily for 28 weeks. For the post hoc analysis, outcomes included the rate and severity of URI defined using the validated Wisconsin Upper Respiratory Symptom Survey [21] .
A total of 408 adults were randomized into the trial [20 & ]. Baseline 25(OH)D levels were 18 and 20 ng/ml in the vitamin D and placebo arms, respectively. Half of study participants (n ¼ 203) experienced at least one URI. The cold severity score, judged using a validated scale, was no different between treatment arms. Similarly, rates of infection were no different between treatment arms (1.24 versus 1.48 colds per person-year in the placebo and vitamin D arms, P ¼ 0.15). Of concern, blacks randomized to vitamin D 3 experienced more URI than those assigned to placebo (rate ratio 1.7, 95% CI 1.1-2.7). Moreover, study participants achieving 25(OH)D levels more than 30 ng/ml at 12 weeks experienced more infections than those not achieving such levels (rate ratio 1.4, 95% CI 1.1-1.7).
Results contrast with another multicenter trial [22] in which 430 Japanese children aged 6-15 years old were randomized to vitamin D 600 IU twice daily or matching placebo, taken from December 2008 to March 2009. Children randomized to vitamin D experienced lower risk of influenza A (rate ratio 0.58, 95% CI 0.34, 0.99) but no lower risk of influenza B, pneumonia, gastroenteritis, or hospitalization. Study limitations included high attrition (22%), high comorbidity (27%), self-reported adherence, and no measurement of serum 25(OH)D.
In summary, the two trials [17 & ,20 & ] in adults conclude that vitamin D does not reduce ARI. Instead, high-dose vitamin D and/or higher serum levels were linked to higher rates and increasing severity of URI. By contrast, wintertime vitamin D therapy seemed to reduce risk of influenza A in children. These contradictory results call for further research, before routine prescription of vitamin D to reduce infections.
Vitamin D and risk of colorectal adenomas
Observational studies have linked higher 25(OH)D levels to lower risk of colon cancer. Researchers therefore hypothesized that vitamin D therapy would reduce the risk of newly identified colon adenomas [23 && ]. Researchers recruited study participants 45-75 years old with a recently detected colon adenoma detected by colonoscopy. Individuals with hyperparathyroidism, nephrolithiasis, osteoporosis, renal disease, and abnormal serum calcium or 25(OH)D levels less than 12 or more than 90 ng/ml were excluded. Study participants were randomized to vitamin D 3 1000 IU, calcium carbonate 1200 mg, both supplements, or placebo daily until their next colonoscopy 3-5 years later. The primary study outcome was the number of adenomas detected on follow-up colonoscopy.
A total of 2259 study participants were randomized into the trial and 2088 (92%) completed all study visits [23 && ]. Although based on self-report rather than pill counts, 87% of study participants reported at least 80% adherence to study medication. A single pathologist blinded to treatment assignment analyzed all specimens excised during follow-up colonoscopy to confirm reported results of the local pathologist.
The risk ratio for new adenomas was no different across the four treatment arms [23 && ]. Among study participants assigned to vitamin D 3 , the risk ratio for new adenomas was 0.99 (95% CI 0.89-1.09) relative to the risk in study participants not taking vitamin D. Similarly, the risk ratio for advanced adenomas with features worrisome for malignancy was 0.99 (95% CI 0.75-1.29) compared with the risk in study participants not assigned to vitamin D. Finally, vitamin D therapy did not reduce the risk of new adenomas among study participants in the lowest quartile for baseline serum 25(OH)D level.
In summary, researchers found no evidence that vitamin D therapy reduced the risk of new adenomas, or advanced adenomas, in adults with pre-existing colon adenomas.
CONCLUSION
Mounting evidence supports the IOM conclusion that vitamin D repletion is defined as a serum 25(OH)D level at least 20 ng/ml. The IOM estimates that repletion can be achieved in nearly all adults by taking the recommended daily allowance for vitamin D (600 IU/day for adults <70 years old and !800 IU/day for adults 70 years old). Further research is needed to clarify the value of measuring bioavailable vitamin D levels in clinical practice, whether vitamin D taken during pregnancy provides long-term gains in BMD for children born in winter, or whether vitamin D reduces risk of influenza. Several recent studies show harm (greater risk of falls or respiratory infections) or no benefit from high-dose vitamin D, calling for caution when prescribing high-dose vitamin D to adults.
